Journals / Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi / 2022 / Cilt: 26 - Sayı: 3

D/L-Homocysteine May Suppress Proliferative Properties of Tamoxifen-resistant MCF-7/TAMR-1 Breast Cancer Cells through Modulation of ER Stress

D/L-Homosistein Tamoksifene Dirençli MCF-7/TAMR-1 Meme Kanseri Hücrelerinin Proliferatif Özelliklerini ER Stresi Aracılı Olarak Baskılayabilir

Pages
413–419
Publication Date
2022-12-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our findings suggest that combined treatment of new molecules that can affect the processes associated with ER stress, with tamoxifen, might be promising alternative approaches to be applied against tamoxifen resistance in breast cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tamoxifen is an important treatment approach that is frequently used in the treatment of breast cancer, but its usage is limited due to changes in receptor expression profiles of breast cancer cells.
📊
Key Findings & Data:Although tamoxifen has an intense clinical application area, 20-30% of breast cancer patients develop resistance to tamoxifen de novo or after treatment for various reasons.
💡
Conclusion & Impact:Our findings suggest that combined treatment of new molecules that can affect the processes associated with ER stress, with tamoxifen, might be promising alternative approaches to be applied against tamoxifen resistance in breast cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ER stresi · MCF-7/TAMR-1 · Meme Kanseri

Abstract

Tamoxifen is an important treatment approach that is frequently used in the treatment of breast cancer, but its usage is limited due to changes in receptor expression profiles of breast cancer cells. Although tamoxifen has an intense clinical application area, 20-30% of breast cancer patients develop resistance to tamoxifen de novo or after treatment for various reasons. Breast cancer is the second cause of cancer-related death among women worldwide, and many people die from breast cancer each year. For this reason, many studies are continuing to increase the sensitivity of breast cancer cells to tamoxifen. Recent studies have pointed out that mechanisms related to endoplasmic reticulum (ER) stress are important key regulators of breast cancer progression and acquired drug resistance. Thus, agents that modulate ER stress are intensively investigated for new treatment approaches to be developed for cancer. In our studies, combined application of D/L-homocysteine with tamoxifen improves tamoxifen sensitivity of MCF-7/TAMR-1 cells, which well-mimic the development of tamoxifen resistance in vitro by ER stress modulation. Our findings suggest that combined treatment of new molecules that can affect the processes associated with ER stress, with tamoxifen, might be promising alternative approaches to be applied against tamoxifen resistance in breast cancer.

Özet

Tamoksifen meme kanseri tedavisinde sıklıkla kullanılan ancak reseptör ifade profillerindeki değişimlere bağlı olarak kullanımı sınırlanan önemli bir tedavi yaklaşımıdır. Her ne kadar tamoksifen klinikte yoğun bir uygulama alanına sahip olsa da meme kanseri hastalarının %20-30'u çeşitli nedenlerle de novo veya tedavi sonrasında tamoksifene karşı direnç geliştirmektedir. Meme kanseri, dünya genelinde kadınlar arasında kansere bağlı ölümlerin ikinci nedenidir ve her yıl birçok kişi meme kanseri nedeniyle yaşamını yitirmektedir. Bu nedenle meme kanseri hücrelerinin tamoksifen duyarlılığını arttırmak üzerine çok sayıda çalışma sürdürülmektedir. Son çalışmalar, endoplazmik retikulum (ER) stresine ilişkin mekanizmaların meme kanserinin ilerlemesinde ve kazanılmış ilaç direncinde önemli anahtar düzenleyiciler olduğuna işaret etmiştir. Bu nedenle ER stresini modüle eden ajanlar meme kanserine yönelik geliştirilecek yeni tedavi yaklaşımları için yoğun olarak araştırılmaktadır. Çalışmalarımızda D/L-homosistein’in tamoksifen ile kombine uygulamasının in vitro da tamoksifene direnç gelişimini iyi mimik eden MCF-7/TAMR-1 hücrelerinde ER stresi modülasyonu yolu ile tamoksifen duyarlılığını geliştirdiği belirlenmiştir. Çalışmamızdan elde edilen bulgular meme kanserinde ER stresi ile ilişkili süreçlere etki edebilecek yeni moleküllerin tamoksifen ile kombine edilerek tamoksifen direncine karşı uygulanacak alternatif yaklaşımlar açısından umut vaat ettiğini önermektedir.

🔖

Cite This Article

ERZURUMLU, Y., DOĞAN, H. K. (2022). D/L-Homocysteine May Suppress Proliferative Properties of Tamoxifen-resistant MCF-7/TAMR-1 Breast Cancer Cells through Modulation of ER Stress. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Cilt: 26 - Sayı: 3, 413–419. https://ajindex.com/articles/863824

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Rivenbark, A. G., O'Connor, S. M., Coleman, W. B. 2013. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. The American journal of pathology, 183(4), 1113–1124
  2. Hong, R., Ma, F., Xu, B., Li, Q., Zhang, P., Yuan, P., Wang, J., Fan, Y., Cai, R. 2014. Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience. Anti-Cancer Drugs, 25(9),1089-1094
  3. Viedma-Rodríguez, R., Baiza-Gutman, L., Salamanca-Gómez, F., Diaz-Zaragoza, M., Martínez-Hernández, G., Ruiz Esparza-Garrido, R., Velázquez-Flores, M. A., Arenas-Aranda, D. 2014. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncology reports, 32(1), 3–15
  4. Chang, M. 2012. Tamoxifen resistance in breast cancer. Biomolecules & therapeutics, 20(3), 256–267
  5. Dorssers, L. C., Van der Flier, S., Brinkman, A., van Agthoven, T., Veldscholte, J., Berns, E. M., Klijn, J. G., Beex, L. V., Foekens, J. A. 2001. Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs, 61(12), 1721–1733
  6. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. 2005. Global cancer statistics, 2002. CA: a cancer journal for clinicians, 55(2), 74–108
  7. Welch, G. N., Loscalzo, J. 1998. Homocysteine and atherothrombosis. The New England journal of medicine, 338(15), 1042–1050
  8. Thambyrajah, J., Townend, J. N. 2000. Homocysteine and atherothrombosis-mechanisms for injury. European heart journal, 21(12), 967–974
  9. Zou, C. G., Banerjee, R. 2005. Homocysteine and redox signaling. Antioxidants & redox signaling, 7(5-6), 547–559
  10. Outinen, P. A., Sood, S. K., Pfeifer, S. I., Pamidi, S., Podor, T. J., Li, J., Weitz, J. I., Austin, R. C. 1999. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood, 94(3), 959–967
  11. Xu, D., Neville, R., Finkel, T. 2000. Homocysteine accelerates endothelial cell senescence. FEBS letters, 470(1), 20–24
  12. Zhang, C., Cai, Y., Adachi, M. T., Oshiro, S., Aso, T., Kaufman, R. J., Kitajima, S. 2001. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. The Journal of biological chemistry, 276(38), 35867–35874
  13. Kruman, I. I., Culmsee, C., Chan, S. L., Kruman, Y., Guo, Z., Penix, L., Mattson, M. P. 2000. Homocysteine elici